Trials / Completed
CompletedNCT02377713
A Single Dose Study of KHK6640 in Japanese Patients With Alzheimer's Disease.
A Phase 1 Randomized, Double-blind, Placebo-controlled, Single Ascending Dose Study of KHK6640 in Japanese Patients With Alzheimer's Disease.
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 20 (actual)
- Sponsor
- Kyowa Kirin Co., Ltd. · Industry
- Sex
- All
- Age
- 55 Years – 84 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics of KHK6640, given as a single dose in Japanese patients with Mild to Moderate Alzheimer's Disease.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | KHK6640 | Single ascending dose administration |
| DRUG | Placebo | Single ascending dose administration |
Timeline
- Start date
- 2015-03-01
- Primary completion
- 2016-09-01
- Completion
- 2016-09-01
- First posted
- 2015-03-04
- Last updated
- 2016-12-07
Locations
1 site across 1 country: Japan
Source: ClinicalTrials.gov record NCT02377713. Inclusion in this directory is not an endorsement.